Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530451882> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2530451882 endingPage "145" @default.
- W2530451882 startingPage "132" @default.
- W2530451882 abstract "We have heard a great deal recently of the BRIC countries (Brazil, Russia, India, China), and the PIGS (Portugal, Italy, Greece, Spain) but now the focus seems to be on the MINT countries, (Malaysia, Indonesia, Nigeria, and Turkey) as the leading emerging economies in the world. Rising labor and other costs now have companies looking for new opportunities in rapid growth markets. But not without specific risks that companies must be willing to take. Corruption, rampant communicable disease, drug abuse and criminal activity, religious issues and disagreements are a few of the challenges companies must face in the new frontier. This paper will attempt to look at four pharmaceutical companies in each of the MINT countries to determine their potential profitability as an investment opportunity. This industry is especially unique since these countries have a growing population which will increase the labor force and also create a need for pharmaceutical products. Each of these countries is located in an advantageous geographical location which will provide an advantage in growing their economies. Mexico is next to the U.S. and the rest of Latin America. Indonesia is located in the heart of Southeast Asia with strong ties to China. Turkey has positioned itself to have both Eastern and Western influences. Nigeria is in a prime spot as it ls located in the prime economic powerhouse of a continent, Africa. If they get their acts together, solve their problems of corruption, energy, and infrastructure, these four countries could potentially overtake China as a leading economy of the world." @default.
- W2530451882 created "2016-10-21" @default.
- W2530451882 creator A5005476490 @default.
- W2530451882 creator A5064992402 @default.
- W2530451882 date "2016-08-31" @default.
- W2530451882 modified "2023-10-15" @default.
- W2530451882 title "MINTS The Next Economic Frontier for Investment – A Financial Analysis of the Pharmaceutical Industry" @default.
- W2530451882 cites W1574402746 @default.
- W2530451882 doi "https://doi.org/10.31686/ijier.vol4.iss8.581" @default.
- W2530451882 hasPublicationYear "2016" @default.
- W2530451882 type Work @default.
- W2530451882 sameAs 2530451882 @default.
- W2530451882 citedByCount "0" @default.
- W2530451882 crossrefType "journal-article" @default.
- W2530451882 hasAuthorship W2530451882A5005476490 @default.
- W2530451882 hasAuthorship W2530451882A5064992402 @default.
- W2530451882 hasBestOaLocation W25304518821 @default.
- W2530451882 hasConcept C10138342 @default.
- W2530451882 hasConcept C121087249 @default.
- W2530451882 hasConcept C124952713 @default.
- W2530451882 hasConcept C129361004 @default.
- W2530451882 hasConcept C136264566 @default.
- W2530451882 hasConcept C142362112 @default.
- W2530451882 hasConcept C144024400 @default.
- W2530451882 hasConcept C144133560 @default.
- W2530451882 hasConcept C149923435 @default.
- W2530451882 hasConcept C158886217 @default.
- W2530451882 hasConcept C162324750 @default.
- W2530451882 hasConcept C17744445 @default.
- W2530451882 hasConcept C191935318 @default.
- W2530451882 hasConcept C199539241 @default.
- W2530451882 hasConcept C27548731 @default.
- W2530451882 hasConcept C2778571376 @default.
- W2530451882 hasConcept C2780027415 @default.
- W2530451882 hasConcept C2908647359 @default.
- W2530451882 hasConcept C47768531 @default.
- W2530451882 hasConcept C50522688 @default.
- W2530451882 hasConcept C94625758 @default.
- W2530451882 hasConceptScore W2530451882C10138342 @default.
- W2530451882 hasConceptScore W2530451882C121087249 @default.
- W2530451882 hasConceptScore W2530451882C124952713 @default.
- W2530451882 hasConceptScore W2530451882C129361004 @default.
- W2530451882 hasConceptScore W2530451882C136264566 @default.
- W2530451882 hasConceptScore W2530451882C142362112 @default.
- W2530451882 hasConceptScore W2530451882C144024400 @default.
- W2530451882 hasConceptScore W2530451882C144133560 @default.
- W2530451882 hasConceptScore W2530451882C149923435 @default.
- W2530451882 hasConceptScore W2530451882C158886217 @default.
- W2530451882 hasConceptScore W2530451882C162324750 @default.
- W2530451882 hasConceptScore W2530451882C17744445 @default.
- W2530451882 hasConceptScore W2530451882C191935318 @default.
- W2530451882 hasConceptScore W2530451882C199539241 @default.
- W2530451882 hasConceptScore W2530451882C27548731 @default.
- W2530451882 hasConceptScore W2530451882C2778571376 @default.
- W2530451882 hasConceptScore W2530451882C2780027415 @default.
- W2530451882 hasConceptScore W2530451882C2908647359 @default.
- W2530451882 hasConceptScore W2530451882C47768531 @default.
- W2530451882 hasConceptScore W2530451882C50522688 @default.
- W2530451882 hasConceptScore W2530451882C94625758 @default.
- W2530451882 hasIssue "8" @default.
- W2530451882 hasLocation W25304518821 @default.
- W2530451882 hasOpenAccess W2530451882 @default.
- W2530451882 hasPrimaryLocation W25304518821 @default.
- W2530451882 hasRelatedWork W1045440851 @default.
- W2530451882 hasRelatedWork W1548797890 @default.
- W2530451882 hasRelatedWork W1557415375 @default.
- W2530451882 hasRelatedWork W2182984971 @default.
- W2530451882 hasRelatedWork W2390448301 @default.
- W2530451882 hasRelatedWork W2515913014 @default.
- W2530451882 hasRelatedWork W2937024682 @default.
- W2530451882 hasRelatedWork W3123369566 @default.
- W2530451882 hasRelatedWork W3123823027 @default.
- W2530451882 hasRelatedWork W3124787201 @default.
- W2530451882 hasVolume "4" @default.
- W2530451882 isParatext "false" @default.
- W2530451882 isRetracted "false" @default.
- W2530451882 magId "2530451882" @default.
- W2530451882 workType "article" @default.